Hyperoside
Based on 26 publication(s) in Google Scholar
Hyperoside is a NF-κB inhibitor, found from Hypericum monogynum. Hyperoside shows anti-tumor, antifungal, anti-inflammatory, anti-viral, and anti-oxidative activities, and can induce apoptosis.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 99.71%
- No. CAS: 482-36-0
- Fòrmula: C21H20O12
- Peso molecular:464.38
-
Almacenamiento:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Pureza y Documentación
- Referencias
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Hyperoside
More- Engineering. 2026 May 20.
- Phytomedicine. 2026 Jul:156:158214. [Abstract]
- Phytomedicine. 2026 Jun:155:158080. [Abstract]
- Phytomedicine. 2026 Apr:153:157952. [Abstract]
- Phytomedicine. 2022 Jul:101:154113. [Abstract]
- Food Chem. 2025 Dec 30:497:146992. [Abstract]
- Food Chem. 2025 Oct 15:489:144992. [Abstract]
- Food Chem. 2023 Mar 30;405(Pt A):134807. [Abstract]
- Chin Med. 2026 Jun 4;21(1):161. [Abstract]
- J Agric Food Chem. 2025 Jun 25;73(25):15561-15578. [Abstract]
- Ind Crops Prod. 2026 May 8;246:123392.
- Ind Crops Prod. 2025 Dec 11;239:122458.
- Life Sci. 2025 Mar 1:364:123417. [Abstract]
- Foods. 2026 Apr 9;15(8):1293. [Abstract]
- Front Pharmacol. 2025 Sep 4:16:1566674. [Abstract]
- Molecules. 2026 Mar 5;31(5):864. [Abstract]
- Mol Med Rep. 2026 Feb;33(2):57. [Abstract]
- Pestic Biochem Physiol. 2025 Dec:215:106655. [Abstract]
- Neuropharmacology. 2025 Mar 15:266:110276. [Abstract]
- Brain Res Bull. 2025 Nov:232:111618. [Abstract]
- Toxicol Appl Pharmacol. 2026 Mar 11:511:117795. [Abstract]
- PeerJ. 2023 May 18:11:e15315. [Abstract]
- Vet Microbiol. 2026 May:316:110992. [Abstract]
- Pol J Microbiol. 2025 Mar 26;74(1):60-70. [Abstract]
- Pharmacogn Mag. 2025 Jan 5.
- Univerzita Karlova v Praz. 2021 Oct.
Customer Validation & Images
-
Cell Imaging/Staining
-
RT-PCR
-
Histological Imaging/Staining
-
ELISA
-
In Vivo Efficacy Study
Actividad biológica
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A549 | IC50 |
>10 μg/mL
Compound: Compound 7
|
Cytotoxicity against human A549 cells by MTT assay
Cytotoxicity against human A549 cells by MTT assay
|
[PMID: 25862199] |
| C2C12 | EC50 |
60.5 μM
Compound: 11
|
Increase in glucose uptake in mouse C2C12 cells incubated for 18 hrs using [3H]-2-deoxy-D-glucose by liquid scintillation counting
Increase in glucose uptake in mouse C2C12 cells incubated for 18 hrs using [3H]-2-deoxy-D-glucose by liquid scintillation counting
|
[PMID: 22738356] |
| HeLa | IC50 |
>10 μg/mL
Compound: Compound 7
|
Cytotoxicity against human HeLa cells by MTT assay
Cytotoxicity against human HeLa cells by MTT assay
|
[PMID: 25862199] |
| MDCK | CC50 |
>431 μM
Compound: Hyperoside
|
Cytotoxicity against MDCK cells
Cytotoxicity against MDCK cells
|
[PMID: 25096296] |
| RAW264.7 | IC50 |
>50 μM
Compound: 16
|
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced TNF-alpha secretion after 18 hrs by sandwich ELISA
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced TNF-alpha secretion after 18 hrs by sandwich ELISA
|
[PMID: 24679441] |
| RAW264.7 | IC50 |
48.8 μM
Compound: 16
|
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 18 hrs by griess reaction analysis
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 18 hrs by griess reaction analysis
|
[PMID: 24679441] |
| SGC-7901 | IC50 |
>10 μg/mL
Compound: Compound 7
|
Cytotoxicity against human SGC7901 cells by MTT assay
Cytotoxicity against human SGC7901 cells by MTT assay
|
[PMID: 25862199] |
Hyperoside (12.5-100 μM; 6-24 h) inhibits MCF-7 and 4T1 cell growth[2].
Hyperoside (25-100 μM; 24 h) induces apoptosis of breast cancer cells[2].
Hyperoside inhibits the activation of the NF-κB signaling pathway via the attenuation of intracellular ROS generation[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:MCF-7 and 4T1 cells
-
Concentration:12.5, 25, 50, 75, or 100 µM
-
Incubation Time:6, 12, or 24 h
-
Result:Inhibited cell growth in a time- and concentration-dependent manner.
-
Cell Line:MCF-7 and 4T1 cells
-
Concentration:25, 50 and 100 µM
-
Incubation Time:24 h
-
Result:Increased the expressions of Bax, cleaved caspase-3 and cleaved PARP, and decreased Bcl-2 in mRNA and protein levels.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Balb/c mice injected with 4T1 cells[2]
-
Dosage:50 mg/kg
-
Administration:Intraperitoneal injection; 50 mg/kg; every two day for 18 days
-
Result:Reduced the average tumor volume compared to the control group.
Decreased Bcl-2 and increased bax and cleaved caspase-3.
Chemical Information
-
No. CAS 482-36-0
-
Appearance Solid
-
Peso molecular 464.38
-
Fòrmula C21H20O12
-
Color Light yellow to yellow
-
SMILES
OC1=CC(O)=C(C(C(O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O2)=C(C3=CC=C(O)C(O)=C3)O4)=O)C4=C1
-
Synonyms
Quercetin 3-O-galactoside; Quercetin 3-O-β-D-galactopyranoside
-
Structure Classification
-
Initial Source
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (26)
-
Journal Impact Factor
-
Most Recent
-
-
Phytomedicine
Hyperoside accelerates myelin debris clearance by inhibiting signal transducer and activator of transcription 3 phosphorylation in peripheral nerve injury. [Abstract]2026 Jul:156:158214. PMID: 42025010 -
Phytomedicine
Hyperoside stabilizes ACAT1 to promote fatty acid oxidation and attenuate kidney fibrosis via the L-carnitine-SIRT3 axis. [Abstract]2026 Jun:155:158080. PMID: 41903436 -
Phytomedicine
Hyperoside as a promising multi-target candidate for neovascular age-related macular degeneration. mechanisms involving Wnt/β-catenin signaling, oxidative stress, and inflammation suppression. [Abstract]2026 Apr:153:157952. PMID: 41720012 -
Phytomedicine
Protective effects of E Se tea extracts against alcoholic fatty liver disease induced by high fat/alcohol diet: In vivo biological evaluation and molecular docking study. [Abstract]2022 Jul:101:154113. PMID: 35490493 -
Food Chem
Effects of sun drying combined with baking processes on the flavor quality of Chongqing Tuocha raw tea. [Abstract]2025 Dec 30:497:146992. PMID: 41285060 -
Food Chem
Flavonoid-mediated metabolic underpinning quality variation in red bud-sport pear mutants. [Abstract]2025 Oct 15:489:144992. PMID: 40466530 -
Food Chem
Discovery of novel ascorbic acid derivatives and other metabolites in fruit of Rosa roxburghii Tratt through untargeted metabolomics and feature-based molecular networking. [Abstract]2023 Mar 30;405(Pt A):134807. PMID: 36370576 -
Chin Med
Hyperoside protects against poly-GR-mediated neurodegeneration via regulation of mitochondrial fission and oxidative stress in C9orf72-associated ALS. [Abstract]2026 Jun 4;21(1):161. PMID: 42243993 -
J Agric Food Chem
High-Pressure and Thermal Pasteurization Applied to Smoothies Enhances (Poly)Phenol Bioaccessibility along the Gastrointestinal Tract. [Abstract]2025 Jun 25;73(25):15561-15578. PMID: 40497562 -
-
-
Life Sci
Hyperoside mitigates PCOS-associated adipogenesis and insulin resistance by regulating NCOA2-mediated PPAR-γ ubiquitination and degradation. [Abstract]2025 Mar 1:364:123417. PMID: 39880157
Hyperoside purchased from MedChemExpress. Usage Cited in: Life Sci. 2025 Mar 1:364:123417. [Abstract]
Hyperoside (HPS) (10 μM; 8 d) significantly inhibited the lipid accumulation induced by MDI in SVF and 3 T3-L1 cells.
Hyperoside purchased from MedChemExpress. Usage Cited in: Life Sci. 2025 Mar 1:364:123417. [Abstract]
Hyperoside (HPS) (10 μM; 8 d) effectively restored the expressions of C/EBPα and FABP4 in SVF and 3 T3-L1 cells to levels comparable to the control.
Hyperoside purchased from MedChemExpress. Usage Cited in: Life Sci. 2025 Mar 1:364:123417. [Abstract]
Low-dose Hyperoside (LHPS) (20 mg/kg; i.p.; 4 weeks) and high-dose Hyperoside (HHPS) (40 mg/kg; i.p.; 4 weeks) treatment markedly decreased the number of cystic follicles in polycystic ovary syndrome (PCOS) mice.
Hyperoside purchased from MedChemExpress. Usage Cited in: Life Sci. 2025 Mar 1:364:123417. [Abstract]
High-dose Hyperoside (HHPS) (40 mg/kg; i.p.; 4 weeks) treatment effectively reversed changes of FSH, LH, progesterone, and testosterone in polycystic ovary syndrome (PCOS) mice, while low-dose Hyperoside (LHPS) (20 mg/kg; i.p.; 4 weeks) improved all hormone levels except FSH.
Hyperoside purchased from MedChemExpress. Usage Cited in: Life Sci. 2025 Mar 1:364:123417. [Abstract]
Both low-dose Hyperoside (LHPS) (20 mg/kg; i.p.; 4 weeks) and high-dose Hyperoside (HHPS) (40 mg/kg; i.p.; 4 weeks) treatments led to a reduction in fasting serum glucose levels and improved insulin sensitivity in polycystic ovary syndrome (PCOS) mice.
-
Foods
Design of a Plant-Based Smoothie: Exploiting Ingredient Complementarity for a Diversified (Poly)phenolic Profile Quantified by Targeted LC-MS/MS Analysis. [Abstract]2026 Apr 9;15(8):1293. PMID: 42073181 -
Front Pharmacol
Hyperoside alleviates myocardial ischemia-reperfusion injury in heart transplantation by promoting mitochondrial fusion via activating the Stat3-Tom70-Opa1 pathway. [Abstract]2025 Sep 4:16:1566674. PMID: 40978492 -
Molecules
2026 Mar 5;31(5):864. PMID: 41828851 -
Mol Med Rep
Hyperoside prevents osteoporosis by activating the PI3K/AKT signaling pathway to inhibit oxidative stress and promote osteogenesis. [Abstract]2026 Feb;33(2):57. PMID: 41347823 -
Pestic Biochem Physiol
Mechanistic insights into chlorogenic acid and caffeic acid as novel juvenile hormone antagonists. [Abstract]2025 Dec:215:106655. PMID: 41162045 -
Neuropharmacology
Hyperoside ameliorates neuropathic pain by modulating the astroglial reactivity in the vlPAG. [Abstract]2025 Mar 15:266:110276. PMID: 39716641 -
Brain Res Bull
Hyperoside alleviates macrophages and microglia-mediated neuroinflammation and oxidative stress through activating PI3K/AKT and Nrf2/HO-1 signaling pathway post spinal cord injury. [Abstract]2025 Nov:232:111618. PMID: 41192740 -
Toxicol Appl Pharmacol
Hyperoside impairs mitochondrial respiration in chronic myeloid leukemia by promoting STUB1-mediated ubiquitination and degradation of NOX4. [Abstract]2026 Mar 11:511:117795. PMID: 41825841 -
PeerJ
Hyperoside alleviates doxorubicin-induced myocardial cells apoptosis by inhibiting the apoptosis signal-regulating kinase 1/p38 pathway. [Abstract]2023 May 18:11:e15315. PMID: 37220525 -
Vet Microbiol
The Chinese medicine monomer Schisandrin C inhibits PRRSV infection by regulating the OGT-PI3K/AKT/mTOR signaling pathway. [Abstract]2026 May:316:110992. PMID: 41865607 -
Pol J Microbiol
Hyperoside Alleviates Helicobacter pylori-Induced Gastric Epithelial Cell Injury by Regulating Nrf2/HO-1 Signaling. [Abstract]2025 Mar 26;74(1):60-70. PMID: 40146790 -
-
Solvente y solubilidad
DMSO : 125 mg/mL (269.18 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (4.48 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (4.48 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 50% PEG300 50% Saline
Solubility: 10 mg/mL (21.53 mM); Clear solution; Need ultrasonic
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureza y Documentación
-
Ficha de datos (283 KB)
-
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
[1]. Li S, et al. Antifungal activity of camptothecin, trifolin, and hyperoside isolated from Camptotheca acuminata. J Agric Food Chem. 2005 Jan 12;53(1):32-7. [Content Brief]
[2]. Qiu J, et al. Hyperoside Induces Breast Cancer Cells Apoptosis via ROS-Mediated NF-κB Signaling Pathway. Int J Mol Sci. 2019 Dec 24;21(1):131. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.1534 mL | 10.7670 mL | 21.5341 mL | 53.8352 mL |
| 5 mM | 0.4307 mL | 2.1534 mL | 4.3068 mL | 10.7670 mL | |
| 10 mM | 0.2153 mL | 1.0767 mL | 2.1534 mL | 5.3835 mL | |
| 15 mM | 0.1436 mL | 0.7178 mL | 1.4356 mL | 3.5890 mL | |
| 20 mM | 0.1077 mL | 0.5384 mL | 1.0767 mL | 2.6918 mL | |
| 25 mM | 0.0861 mL | 0.4307 mL | 0.8614 mL | 2.1534 mL | |
| 30 mM | 0.0718 mL | 0.3589 mL | 0.7178 mL | 1.7945 mL | |
| 40 mM | 0.0538 mL | 0.2692 mL | 0.5384 mL | 1.3459 mL | |
| 50 mM | 0.0431 mL | 0.2153 mL | 0.4307 mL | 1.0767 mL | |
| 60 mM | 0.0359 mL | 0.1795 mL | 0.3589 mL | 0.8973 mL | |
| 80 mM | 0.0269 mL | 0.1346 mL | 0.2692 mL | 0.6729 mL | |
| 100 mM | 0.0215 mL | 0.1077 mL | 0.2153 mL | 0.5384 mL |
Hyperoside Related Classifications
HY-N0452 Related Classifications
Powered by Bioz